REACHnet partnered with University of Florida on a study called “PCSK9 Inhibitor Use in the Real World: Data from the National Patient Centered Research Network (PCORnet)” which used electronic health record data to characterize the early utilization of PCSK9 inhibitors in addition to standard lipid lowering therapies among patients with varying degrees of cardiovascular risk. Data for this study were collected from eighteen geographically diverse healthcare systems. Results and publications are available on the study page on PCORI’s website.